Retrospective analysis of risks and benefits of trimethoprim/sulfamethoxazole as prophylaxis for Pneumocystis jiroveci pneumonia in patients with dermatologic disease

J Am Acad Dermatol. 2023 Jun;88(6):1392-1393. doi: 10.1016/j.jaad.2023.01.041. Epub 2023 Feb 15.

Authors

Mohammed Moumen¹, Laura A Andrews², Yu Wang³, Wasim Haidari³, Joseph L Jorizzo³

Affiliations

¹ Wake Forest School of Medicine, Winston-Salem, North Carolina. Electronic address: mmoumen@wakehealth.edu.
² MSCR and College of Medicine, Medical University of South Carolina, Charleston, South Carolina.
³ Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

PMID: 36796726
DOI: 10.1016/j.jaad.2023.01.041

No abstract available

Keywords: adverse effects; antibiotic premedication; dermatology; drug reactions; prednisone; trimethoprim-sulfamethoxazole.

MeSH terms

Humans
Pneumocystis carinii*
Pneumonia, Pneumocystis* / prevention & control
Retrospective Studies
Risk Assessment
Trimethoprim, Sulfamethoxazole Drug Combination / adverse effects

Substances

Trimethoprim, Sulfamethoxazole Drug Combination